Widely used:Recently Viewed
Clear All$0.01
$0.00
(-38.14%)
As on 21-Mar-2025 16:25EDT
Today’s Range
52 Week Range
Liquidity
Market cap
$----
P/E Ratio
--
P/B Ratio
0
Industry P/E
--
Debt to Equity
0.67
ROE
-5.77 %
ROCE
-162.55 %
Div. Yield
0 %
Book Value
0.01
EPS
-0.03
CFO
£-40.82 Mln
EBITDA
£-45.67 Mln
Net Profit
£-34.02 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
TC BioPharm (Holdings) plc Warrants (TCBPW)
| -39.39 | -64.91 | -60.26 | -84.08 | -75.34 | -- | -- |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
2024
|
2023
|
|
|---|---|---|
|
TC BioPharm (Holdings) plc Warrants (TCBPW)
| -69.24 | -76.79 |
|
BSE Sensex
| 8.10 | 18.74 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified... gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. Read more
CEO & Director
Mr. Bryan Leland Kobel
CEO & Director
Mr. Bryan L. Kobel
Headquarters
Motherwell
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of TC BioPharm (Holdings) plc Warrants (TCBPW) stood at $ 9 Mln as on 31-Dec-23
The share price of TC BioPharm (Holdings) plc Warrants (TCBPW) is $0.01 (NASDAQ) as of 21-Mar-2025 16:25 EDT. TC BioPharm (Holdings) plc Warrants (TCBPW) has given a return of -75.34% in the last 3 years.
TC BioPharm (Holdings) plc Warrants (TCBPW) has a market capitalisation of -- as on 21-Mar-2025. As per Value Research classification, it is a company.
Since, TTM earnings of TC BioPharm (Holdings) plc Warrants (TCBPW) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the TC BioPharm (Holdings) plc Warrants (TCBPW) and enter the required number of quantities and click on buy to purchase the shares of TC BioPharm (Holdings) plc Warrants (TCBPW).
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
The CEO & director of Mr. Bryan Leland Kobel. is TC BioPharm (Holdings) plc Warrants (TCBPW), and CFO & Sr. VP is Mr. Bryan L. Kobel.
There is no promoter pledging in TC BioPharm (Holdings) plc Warrants (TCBPW).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| TC BioPharm (Holdings) plc Warrants (TCBPW) | Ratios |
|---|---|
|
Return on equity(%)
|
-391.64
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of TC BioPharm (Holdings) plc Warrants (TCBPW) was No Profit.
